Ionis Pharmaceuticals

Ionis Pharmaceuticals

  • July 2020 •
  • 36 pages •
  • Report ID: 5955610 •
  • Format: PDF
PharmaVitae explores Ionis Pharmaceuticals’ prescription pharmaceutical performance and outlook over 2019–29.

Snapshot
Overview – Ionis’s prescription pharmaceutical business will see strong growth over the forecast period.
Key themes – [1] Spinraza royalties will comprise the majority of Ionis’s revenues for the foreseeable future [2] Pharmaceutical business growth driven by launches of Tegsedi and Waylivra.

Model updates (6 May 2020)

No changes to forecast.

Model updates (26 February 2020)

Waylivra forecast adjusted lower due to slower-than-anticipated launch.

Model updates (11 November 2019)

Waylivra US launch delayed until 2022
Tegsedi forecast adjusted lower due to slower-than-anticipated launch.

Model updates (12 July 2019)

Tegsedi sales adjusted lower due to pace of sales ramp
Waylivra launch delayed in the five major EU markets until Q3 2019, and in RoW until Q1 2020.